8. Baseline Characteristics 54.154.6Current or Former Smoker 25.625.0Diabetic 67.467.1Hypertension 25.7 Prior MI 13.913.8Prior Heart Failure 54.454.9Suspected MI w/o ST elevation 62.061.4Male 1005710021No. Rand. 80.679.8ECG with ischemia 24.625.1T wave inversion (>3 mm) 51.750.3 ST depression  1mm 70.370.5Troponinor CKMB > ULN Fonda (%)Enox(%)Outcome

9. Therapies During Initial Hospitalization 41.741.0During PCI 78.577.5Statins 74.976.1ACE Inhibitors/ARB 26.926.8Calcium Channel Blockers 87.287.7Beta-blockers 67.667.2Clopididogrel/Ticlopidine 18.617.6GPIIb/IIIaInhib 97.5 ASA 1005710021No. Rand. Fonda (%)Enox(%) 70% of patients recruited from centers withcathlabs

10. Days of Study Treatment Compliance and Duration 5.4 (2.4)5.2 (2.3) FondaEnox Mean No. of days of therapy (SD) % who received > 1 dose of drug 99.2%99.4%

12. Primary Efficacy Outcome Death/MI/RI at Day 9 0.811.2 1.01 1.13 0.90 P-Value for Non-Inferiority=0.007 Non-inferiority Margin=1.185 Hazard Ratio Fonda BetterEnoxBetter

13. Efficacy Outcomes at Day 9 5.8%5.7% Death/MI/RI 1.9% Refract Isch 2.6%2.7% MI 1.8%1.9% Death 4.1% Death/MI FondaEnox 0.811.2 Non-inferiority Margin=1.185 Hazard Ratio Fonda BetterEnoxBetter

15. Major Bleeding: 9 Days Days Cumulative Hazard 0.0 0.01 0.02 0.03 0.04 0123456789 HR 0.52 95% CI 0.44-0.61 P<0.001 Enoxaparin Fondaparinux

16. Categories of Major Bleeds at 9 Days 164282 Transfusion  2 units 152315  Hb  3g/dL <0.001 P 217 (2.2%)412 (4.1%)Total Bleeding 936Retroperitoneal 1005710021No. Rand. 4073Surgeryreq’dto stop bleed 77Intracranial Fonda (No. Pts) Enox (No. Pts)

17. No. of Patients Receiving Transfusions 1005710021No. Randomized 338 (3.4%) 134 (1.3%) 57 (0.6%) 133 (1.3%) 14 (0.1%) Fonda No. (%) 433 (4.3%)Any transfusion 166 (1.7%)4+ Units 56 (0.6%)3 Units 183 (1.9%)2 Units 24 (0.2%)1 Unit Enox No. (%)

18. Efficacy-Safety Balance Death/MI/RI/MajBleed: Day 9 Days Cumulative Hazard 0.0 0.02 0.04 0.06 0.08 0123456789 HR 0.82 HR 0.81 95% CI 0.74 95% CI 0.73 - - 0.90 0.89 P<0.001 Enoxaparin Fondaparinux

19. Efficacy Outcomes at Day 30 Death/MI/Stroke Strokes 8.0%8.6%Death/MI/RI 2.2% RI 3.9%4.1%MI 2.9%3.5%Death 6.2%6.8%Death/MI FondaEnox P=0.02 P=0.07 0.81 1.2 P=0.002

20. Mortality: Day 30 Days Cumulative Hazard 0.0 0.01 0.02 0.03 036912151821242730 HR 0.83 95% CI 0.71 - - 0.97 P=0.02 Enoxaparin Fondaparinux

21. Major Bleeding: Day 30 Days Cumulative Hazard 0.0 0.01 0.02 0.03 0.04 0.05 036912151821242730 HR 0.63 HR 0.62 95% CI 0.55 95% CI 0.54 - - 0.73 0.72 P<0.001 Enoxaparin Fondaparinux

22. Death/MI/RI/Major Bleeds: Day 30 Days Cumulative Hazard 0.0 0.02 0.04 0.06 0.08 0.10 0.12 036912151821242730 HR 0.83 HR 0.82 95% CI 0.76 95% CI 0.75 - - 0.90 0.89 P<0.001 Enoxaparin Fondaparinux

23. Efficacy at 6 Months 0.811.2 11.1%12.5% Death/MI/Stroke 12.3%13.2% Death/MI/RI 1.3%1.7% Strokes 6.3%6.6% MI 5.8%6.5% Death 10.5%11.4% Death/MI FondaEnox 0.06 0.05 0.04 0.007 P value

24. Death or MI: 6 Months Days Cumulative Hazard 0.0 0.02 0.04 0.06 0.08 0.10 0.12 020406080100120140160180 HR 0.91 HR 0.92 95% CI 0.84 - P=0.05 Enoxaparin Fondaparinux

25. Mortality at 6 Months Days Cumulative Hazard 0.0 0.02 0.04 0.06 020406080100120140160180 HR 0.89 95% CI 0.79 95% CI 0.80 - - 1.00 P=0.05 Enoxaparin Fondaparinux

26. Major Bleeding: 6 Months Days Cumulative Hazard 0.0 0.01 0.02 0.03 0.04 0.05 0.06 020406080100120140160180 HR 0.72 95% CI 0.64 - - 0.82 P<0.001 Enoxaparin Fondaparinux

27. Death, MI, RI,MajorBleeding at 6 Months Days Cumulative Hazard 0.0 0.05 0.10 0.15 020406080100120140160180 Enoxaparin Fondaparinux HR 0.87 HR 0.86 95% CI 0.81 - - 0.93 P<0.001

30. Patients Undergoing PCI within the First 8 Days of Randomization 2348 (74.9%)2317 (74.6%)Thienopyridines 1308 (41.7%)1273 (41.0%)GP Iib/IIIa inhibitor 651 (20.8%)1724 (55.5%)Unfractionated heparin No. of events (% of patients) Concomitant antithrombotic drugs Fondaparinux (n=3135) Enoxaparin (n=3104)

31. Patients Undergoing PCI within the First 8 Days of Randomization 0.0013.59 (1.64-7.84)29 (0.9%)8 (0.4%) All catheter-related thrombi 0.082.99 (0.81-11.04)9 (0.3%)3 (0.1%) Catheter-related thrombus not resulting in clinical complications 1.16 (0.94-1.42)188 (6.0%)161 (5.2%) Abrupt closure, new thrombus with reduced flow, dissection, or no reflow 0.211.11 (0.94-1.29)299 (9.5%)268 (8.6%) Any complication PCI-related coronary complication 0.36 (0.26-0.49)50 (1.6%)138 (4.4%) Large hematoma 0.63 (0.40-0.98)31 (1.0%)49 (1.6%) Pseudoaneurysm <0.0010.41 (0.33-0.51)103 (3.3%)251 (8.1%) Any complication No. of events (% of patients) Complications involving the vascular access site P Value Relative Risk (95% CI) Fondaparinux (n=3135) Enoxaparin (n=3104)

32. Patients Undergoing PCI within the First 8 Days of Randomization 0.0030.79 (0.67-0.92)255 (8.2%)321 (10.3%) Death, MI, stroke or major bleeding 1.03 (0.87-1.25)198 (6.3%)190 (6.1%)Death, MI or stroke 0.99 (0.46-2.13)13 (0.4%) Stroke 0.45 (0.34-0.59)72 (2.3%)158 (5.1%)Major Bleeding <0.0010.81 (0.73-0.90)521 (16.6%)638 (20.6%) Any procedural complication, major bleeding, death, MI or stroke 1.04 (0.84-1.28)161 (5.1%)154 (5.0%)MI 0.96 (0.62-1.51)37 (1.2%)38 (1.2%)Death No. of events (% of patients) Clinical Events at 9 days P Value Relative Risk (95% CI) Fondaparinux (n=3135) Enoxaparin (n=3104)

33. Patients Undergoing PCI within the First 8 Days of Randomization 0.0040.81 (0.70-0.93)297 (9.5%)364 (11.7%) Death, MI, stroke or major bleeding 1.00 (0.84-1.20)231 (7.4%)228 (7.3%)Death, MI or stroke 0.51 (0.40-0.66)87 (2.8%)169 (5.4%)Major Bleeding 0.81 (0.44-1.51)18 (0.6%)22 (0.7%)Stroke 1.05 (0.86-1.29)179 (5.7%)169 (5.4%)MI 0.94 (0.67-1.33)62 (2.0%)65 (2.1%)Death No. of events (% of patients) Clinical Events at 30 days P Value Relative Risk (95% CI) Fondaparinux (n=3135) Enoxaparin (n=3104)

35. Clinical Implications THE OASIS 5 TRIAL CLEARLY DEMONSTRATES THAT FONDAPARINUX IS THE PREFERRED ANTICOAGULANT FOR TREATMENT OF ACS